CPHI Japan, a leading global pharmaceutical exhibition, opened on April 21. Led by the Department of Industrial Technology (DoIT) under the Ministry of Economic Affairs (MOEA), 16 leading biomedical companies formed the Taiwan Pharma Pavilion to expand their presence in the Asia-Pacific market.
During the opening ceremony, Chien-Cheng Tai, Senior Specialist at DoIT, noted that 2026 marks a pivotal year for Taiwan’s pharmaceutical industry as it expands beyond its R&D strengths to build a more complete global supply chain presence. As part of this effort, the MOEA is promoting a two-stage international outreach strategy: Japan will serve as the entry point for regulatory alignment and early market access, while Milan in Italy will act as a global manufacturing hub, linking international pharmaceutical companies with Taiwan’s strong CDMO ecosystem. This approach aims to integrate Taiwan more deeply into the global pharmaceutical supply chain while highlighting its advantages in manufacturing flexibility and technological integration.
Shyue-Yow Chou, Deputy Representative of the Taipei Economic and Cultural Representative Office in Japan, added that the partnership enables both sides to leverage complementary strengths and strengthen their roles in the global pharmaceutical supply chain. Toshio Fujimoto, CEO of iPark Institute, emphasized that Taiwan’s robust R&D capabilities, comprehensive manufacturing base, and rich clinical resources make it a highly promising partner for advancing global pharmaceutical innovation.
News Resources: https://www.moea.gov.tw/MNS/populace/news/News.aspx?kind=1&menu_id=40&news_id=122469
